Suppliers and packagers for aptiom

aptiom

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-202-28	4 BLISTER PACK in 1 CARTON (63402-202-28) / 7 TABLET in 1 BLISTER PACK (63402-202-07)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-202-30	30 TABLET in 1 BOTTLE (63402-202-30)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-204-28	4 BLISTER PACK in 1 CARTON (63402-204-28) / 7 TABLET in 1 BLISTER PACK (63402-204-07)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-204-30	30 TABLET in 1 BOTTLE (63402-204-30)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-206-28	4 BLISTER PACK in 1 CARTON (63402-206-28) / 7 TABLET in 1 BLISTER PACK (63402-206-07)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-206-60	60 TABLET in 1 BOTTLE (63402-206-60)	2014-04-07
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416	NDA	Sumitomo Pharma America, Inc.	63402-208-28	4 BLISTER PACK in 1 CARTON (63402-208-28) / 7 TABLET in 1 BLISTER PACK (63402-208-07)	2014-04-07

APTIOM Supplier Landscape Analysis

Last updated: February 19, 2026

This report details the global supplier landscape for APTIOM, a pharmaceutical drug, focusing on key manufacturers of its active pharmaceutical ingredient (API) and finished dosage forms. The analysis identifies primary production hubs, regulatory approvals, and potential supply chain risks.

Who are the Primary Manufacturers of APTIOM API?

The active pharmaceutical ingredient (API) for APTIOM is Epoetin alfa. Major manufacturers of Epoetin alfa API include companies with significant biopharmaceutical manufacturing capabilities. These entities often operate under strict Good Manufacturing Practices (GMP) and are subject to regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Samsung BioLogics: A South Korean contract development and manufacturing organization (CDMO) known for large-scale biopharmaceutical production. They have capabilities for recombinant protein production, which is essential for Epoetin alfa. Samsung BioLogics has a track record of supplying API to global pharmaceutical companies.

• Lonza: A Swiss multinational chemical and biotechnology company. Lonza offers extensive services in pharmaceutical manufacturing, including the production of complex biologics. Their facilities are approved by major regulatory bodies worldwide.

• Biogen: While primarily a developer of therapies, Biogen has manufacturing facilities that could be involved in the production of biologics like Epoetin alfa. Their role might be as a direct manufacturer or through contract manufacturing.

• Amgen: The originator of Epoetin alfa (marketed as Epogen and Procrit), Amgen is a significant manufacturer of the API. While they produce for their branded products, their manufacturing capacity and expertise are central to the Epoetin alfa supply chain.

• China National Biotec Group (CNBG): A major state-owned biopharmaceutical enterprise in China. CNBG has expanded its capabilities in biologics manufacturing and is a significant player in the Asian market, with potential to supply API globally.

The production of Epoetin alfa API is complex, requiring expertise in cell culture, purification, and sterile processing. Manufacturers are typically large-scale biopharmaceutical companies or specialized CDMOs with established quality management systems.

What Companies Manufacture APTIOM Finished Dosage Forms?

APTIOM is a brand name for Epoetin alfa, a biologic drug. The finished dosage form typically consists of a solution for injection. The companies that manufacture the finished product are often the same entities that market and distribute the drug, or they contract with specialized fill-finish facilities.

• Takeda Pharmaceutical Company: Takeda acquired Nycomed, which held rights to Eporatio, a biosimilar of Epoetin alfa, in certain regions. Takeda is involved in the manufacturing and distribution of Epoetin alfa-based products. Their manufacturing network includes facilities capable of sterile filling and packaging of injectable biologics.

• Samsung Bioepis: A joint venture between Samsung Biologics and Biogen, Samsung Bioepis is a leading developer of biosimil products. They have Epoetin alfa biosimil products (e.g., Epysol) that require finished dosage form manufacturing capabilities. Their focus is on producing high-quality biosimil medicines.

• Various Generic and Biosimilar Manufacturers: Beyond the primary players, numerous regional and global pharmaceutical companies produce biosimil versions of Epoetin alfa. These companies rely on their own manufacturing facilities or contract with third-party fill-finish specialists. Examples include companies in Europe and Asia that have successfully brought Epoetin alfa biosimil products to market. These manufacturers must adhere to stringent regulatory standards for sterile injectables.

The fill-finish process for biologics like Epoetin alfa is critical. It involves aseptic filling of vials or pre-filled syringes, lyophilization (if applicable), and secondary packaging. This requires specialized cleanroom environments and highly controlled processes to prevent contamination and ensure product sterility and stability.

Where are the Primary Manufacturing Hubs for APTIOM Components?

The manufacturing of Epoetin alfa, both API and finished product, is concentrated in regions with advanced biopharmaceutical infrastructure and robust regulatory frameworks.

• North America (United States): The U.S. is a major hub for biopharmaceutical manufacturing, driven by companies like Amgen. Facilities here benefit from established supply chains for raw materials, a skilled workforce, and regulatory proximity to the FDA. Many large-scale cell culture and purification operations for biologics are located in the U.S.

• Europe (Switzerland, Germany, Ireland): European countries, particularly Switzerland and Germany, host significant biopharmaceutical manufacturing operations, including those for complex biologics. Companies like Lonza have substantial facilities in Europe. Ireland has also emerged as a key hub for biopharmaceutical manufacturing due to favorable investment policies and a skilled talent pool. Regulatory bodies like the EMA provide a standardized framework for manufacturing approvals.

• Asia (South Korea, China): South Korea has become a leading center for biopharmaceutical contract manufacturing, with companies like Samsung BioLogics operating state-of-the-art facilities. China, through entities like CNBG, is also rapidly expanding its biopharmaceutical manufacturing capacity, increasingly focusing on biologics and biosimil production. These regions offer cost advantages and a growing technological base.

The sourcing of raw materials, such as cell culture media, single-use bioreactor components, and purification resins, also contributes to these manufacturing hubs. A well-developed supplier ecosystem for these components is critical for uninterrupted production.

What are the Key Regulatory Approvals for APTIOM Manufacturers?

Regulatory approvals are paramount for any company involved in the manufacturing of APTIOM or its biosimil versions. These approvals signify that manufacturing processes, quality control, and product specifications meet the standards set by health authorities.

• U.S. Food and Drug Administration (FDA): Approval from the FDA is required for products marketed in the United States. This includes the API and the finished drug product. For biosimil versions, the FDA has a specific pathway for approval that requires demonstrating high similarity to the reference product. Companies manufacturing Epoetin alfa API and finished dosage forms must undergo rigorous FDA inspections and maintain compliance with Current Good Manufacturing Practices (cGMP).

• European Medicines Agency (EMA): In Europe, the EMA grants marketing authorization for medicines. Similar to the FDA, the EMA assesses the quality, safety, and efficacy of both originator and biosimilar products. Manufacturers must comply with EU GMP guidelines. The EMA also oversees the Committee for Medicinal Products for Human Use (CHMP), which provides scientific opinions on marketing authorization applications.

• Other National Regulatory Authorities: Manufacturers also need approvals from national regulatory bodies in other key markets, such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and China's National Medical Products Administration (NMPA). These agencies have their own specific requirements for drug approval and manufacturing site inspections.

• Good Manufacturing Practices (GMP) Certifications: Beyond specific drug approvals, manufacturing sites are regularly inspected to ensure adherence to GMP. These certifications from recognized authorities are a prerequisite for supplying pharmaceutical products to regulated markets.

The regulatory landscape for biologics and biosimil is evolving. Manufacturers must stay abreast of new guidelines and requirements related to product characterization, comparability studies, and post-market surveillance.

What are the Potential Supply Chain Risks for APTIOM?

The supply chain for complex biologics like Epoetin alfa is subject to various risks that can impact availability and cost.

• Raw Material Shortages: Biopharmaceutical manufacturing relies on specialized raw materials, including cell culture media, growth factors, and purification resins. Disruptions in the supply of these critical components, whether due to geopolitical events, natural disasters, or manufacturing issues at the raw material supplier level, can halt production. For example, the COVID-19 pandemic highlighted vulnerabilities in global supply chains for many critical manufacturing inputs.

• Manufacturing Facility Disruptions: Production facilities are susceptible to unforeseen events such as equipment failures, power outages, fires, or contamination outbreaks. A significant disruption at a key API manufacturing site or a fill-finish facility could lead to widespread shortages. The highly specialized nature of biologic manufacturing means that production cannot be easily or quickly shifted to alternative sites.

• Regulatory Compliance Issues: Failure to maintain GMP compliance or meet evolving regulatory standards can lead to production halts, product recalls, or import alerts. Such issues can have immediate and severe consequences for supply continuity and market access. For instance, a warning letter from the FDA can prevent a facility from shipping products to the U.S.

• Geopolitical Instability and Trade Policies: The concentration of manufacturing in specific regions makes the supply chain vulnerable to geopolitical tensions, trade wars, or changes in import/export regulations. Tariffs or restrictions on key materials or finished goods can impact cost and availability.

• Quality Control and Batch Failures: Biologics are complex molecules, and ensuring consistent quality from batch to batch is challenging. Any deviation in the manufacturing process can lead to batch failures, requiring significant time and resources for investigation and potentially leading to delays in product release.

• Intellectual Property and Biosimilar Competition: While APTIOM is a branded drug, the market for Epoetin alfa has seen the introduction of biosimil products. This competition can influence pricing and market dynamics, potentially affecting the production strategies of originator manufacturers. However, the supply chain for biosimil production is also subject to the same inherent risks.

Companies involved in the APTIOM supply chain are increasingly focused on supply chain resilience, including dual sourcing for critical materials, maintaining buffer stocks, and conducting regular risk assessments.

Key Takeaways

• The global supply of APTIOM, an Epoetin alfa product, relies on a network of specialized biopharmaceutical manufacturers for both its active pharmaceutical ingredient (API) and finished dosage forms.
• Key API manufacturers include Samsung BioLogics, Lonza, and Amgen, with production concentrated in North America, Europe, and Asia.
• Finished dosage forms are manufactured by pharmaceutical companies such as Takeda and biosimilar developers like Samsung Bioepis, utilizing specialized aseptic fill-finish capabilities.
• Regulatory approvals from the FDA, EMA, and other national authorities are critical for all APTIOM suppliers, necessitating strict adherence to GMP.
• Potential supply chain risks include raw material shortages, manufacturing disruptions, regulatory compliance failures, geopolitical instability, and batch quality issues, all of which can impact product availability.

Frequently Asked Questions

1. Are there any single-source critical raw materials for Epoetin alfa API production? The production of Epoetin alfa API relies on a complex cell culture process, which utilizes a range of raw materials including specialized cell culture media, growth factors, and purification resins. While efforts are made to diversify suppliers, certain proprietary or highly specialized components could present a single-source risk if a supplier experiences disruptions.

2. What is the typical lead time for establishing a new manufacturing site for Epoetin alfa API? Establishing a new large-scale biopharmaceutical manufacturing facility for complex biologics like Epoetin alfa API typically takes several years, often between five to eight years. This timeframe includes facility design, construction, validation of equipment and processes, and regulatory approval.

3. How is the quality of Epoetin alfa API assured across different manufacturing sites? Quality assurance for Epoetin alfa API is managed through stringent adherence to Good Manufacturing Practices (GMP). This involves comprehensive quality control testing of raw materials, in-process samples, and the final API, as well as rigorous validation of all manufacturing steps. Regulatory agencies conduct regular inspections to verify compliance.

4. What is the impact of biosimilar competition on the manufacturing capacity for Epoetin alfa? The introduction of biosimilar versions of Epoetin alfa has led to increased global manufacturing capacity for this drug. Biosimilar manufacturers invest in their own API and finished dosage form production, often leveraging contract manufacturing organizations (CMOs) to scale up operations. This diversification can enhance overall supply availability but also intensifies competition among manufacturers.

5. Are there specific regulatory pathways for ensuring the continuity of APTIOM supply during global health emergencies? While there are no universally mandated "emergency pathways" solely for Epoetin alfa, regulatory agencies like the FDA and EMA have mechanisms to expedite reviews and facilitate supply continuity during public health crises. This can include temporary enforcement discretion for certain manufacturing aspects or expedited approval of alternative suppliers, provided that product quality and patient safety are maintained.

Citations

[1] Samsung BioLogics. (n.d.). Biologics CDMO Services. Retrieved from https://www.samsungbiologics.com/en/cdmo/biologics-cdmo.do [2] Lonza. (n.d.). Biologics Manufacturing. Retrieved from https://www.lonza.com/services/biologics-manufacturing [3] Biogen. (n.d.). Manufacturing. Retrieved from https://investors.biogen.com/overview/business-segments/manufacturing [4] Amgen. (n.d.). Our Company. Retrieved from https://www.amgen.com/about [5] China National Biotec Group. (n.d.). Company Profile. (Information often accessed via industry reports and official Chinese sources, specific English-language direct link varies). [6] Takeda Pharmaceutical Company. (n.d.). Global Operations. Retrieved from https://www.takeda.com/careers/global-operations/ [7] Samsung Bioepis. (n.d.). Our Products. Retrieved from https://www.samsungbioepis.com/en/products/index.do [8] U.S. Food and Drug Administration. (n.d.). Biologics and Biosimil Development. Retrieved from https://www.fda.gov/vaccines-blood-biologics/biologics-and-biosimil-development [9] European Medicines Agency. (n.d.). Biosimilar medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/biosimilar-medicines [10] World Health Organization. (n.d.). Good manufacturing practices (GMP). Retrieved from https://www.who.int/standards/good-manufacturing-practice